| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c2f97d7c34edcd6aa0070584b41438e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a4108a152e746ebe3904c3610fad89a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca9779141d034b8375a54819950df9b5 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
1995-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1996-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d0a4c3ee64c8e84c4056b324fee9ddc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80274829bf79a8520e60f3e7cf7de9ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7cfb83620711aded25c49b98bf041d4 |
| publicationDate |
1996-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2058153-C1 |
| titleOfInvention |
Preparation for primary liver cancer treatment |
| abstract |
FIELD: medicine. SUBSTANCE: proposed preparation is alpha-fetoprotein used at the dose 15 mg intraarterially at 12 days intervals, five-fold. Proposed chemiotherapy course used alpha-fetoprotein promotes the favorable disease run. As a result of treatment tumor disappears, metastasis are absent. EFFECT: enhanced effectiveness of treatment. 1 tbl |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6878688-B2 |
| priorityDate |
1995-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |